These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23503653)

  • 1. Considerations in selecting rapid-onset opioids for the management of breakthrough pain.
    Smith HS
    J Pain Res; 2013; 6():189-200. PubMed ID: 23503653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review of rapid-onset opioids for breakthrough pain.
    Smith H
    CNS Drugs; 2012 Jun; 26(6):509-35. PubMed ID: 22668247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the pharmacokinetic profile of transmucosal fentanyl formulations.
    Moore N; Darwish M; Amores X; Schneid H
    Curr Med Res Opin; 2012 Nov; 28(11):1781-90. PubMed ID: 23020252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacoeconomics of breakthrough cancer pain.
    Kuo KL; Saokaew S; Stenehjem DD
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):167-75. PubMed ID: 23688496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain.
    Prommer E; Ficek B
    Patient Prefer Adherence; 2012; 6():465-75. PubMed ID: 22791984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for breakthrough cancer pain.
    Mercadante S
    Drugs; 2012 Jan; 72(2):181-90. PubMed ID: 22233484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of rapid-onset opioids for breakthrough pain in patients with cancer.
    Simon SM; Schwartzberg LS
    J Opioid Manag; 2014; 10(3):207-15. PubMed ID: 24944071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of breakthrough pain.
    McCarberg BH
    Pain Med; 2007; 8 Suppl 1():S8-13. PubMed ID: 17280601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
    Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
    Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl sublingual spray for breakthrough pain in cancer patients.
    Zeppetella G
    Pain Ther; 2013 Jun; 2(1):1-9. PubMed ID: 25135032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
    Corli O; Roberto A
    Minerva Anestesiol; 2014 Oct; 80(10):1123-34. PubMed ID: 24346227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.